Alseres Pharmaceuticals Stock Forecast, Price & News

0.00 (0.00 %)
(As of 04/19/2021 12:00 AM ET)
Today's Range
Now: $6.00
50-Day Range
MA: $6.00
52-Week Range
Now: $6.00
Average Volume100 shs
Market Capitalization$36,000.00
P/E RatioN/A
Dividend YieldN/A
Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:ALSE
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$36,000.00
Next Earnings DateN/A
OptionableNot Optionable


Global Radiopharmaceuticals Industry
November 24, 2020 |  markets.businessinsider.com
See More Headlines


Overall MarketRank

0.00 out of 5 stars

Medical Sector

1845th out of 2,018 stocks

Pharmaceutical Preparations Industry

736th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
0.00 (0.00 %)
(As of 04/19/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALSE News and Ratings via Email

Sign-up to receive the latest news and ratings for ALSE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Alseres Pharmaceuticals (OTCMKTS:ALSE) Frequently Asked Questions

What stocks does MarketBeat like better than Alseres Pharmaceuticals?

Wall Street analysts have given Alseres Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Alseres Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Alseres Pharmaceuticals' key executives?

Alseres Pharmaceuticals' management team includes the following people:
  • Mr. Peter G. Savas, Exec. Chairman (Age 73)
  • Mr. Sam Martin, Director of Fin. & Corp. Compliance

Who are some of Alseres Pharmaceuticals' key competitors?

What other stocks do shareholders of Alseres Pharmaceuticals own?

What is Alseres Pharmaceuticals' stock symbol?

Alseres Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ALSE."

How do I buy shares of Alseres Pharmaceuticals?

Shares of ALSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alseres Pharmaceuticals' stock price today?

One share of ALSE stock can currently be purchased for approximately $6.00.

How much money does Alseres Pharmaceuticals make?

Alseres Pharmaceuticals has a market capitalization of $36,000.00.

How many employees does Alseres Pharmaceuticals have?

Alseres Pharmaceuticals employs 3 workers across the globe.

What is Alseres Pharmaceuticals' official website?

The official website for Alseres Pharmaceuticals is www.alseres.com.

Where are Alseres Pharmaceuticals' headquarters?

Alseres Pharmaceuticals is headquartered at 275 GROVE STREET SUITE 2-400, AUBURNDALE MA, 02466.

How can I contact Alseres Pharmaceuticals?

Alseres Pharmaceuticals' mailing address is 275 GROVE STREET SUITE 2-400, AUBURNDALE MA, 02466. The company can be reached via phone at 617-419-3289 or via email at [email protected]

This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.